Zugriffe | |
---|---|
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 162 |
Oktober 2023 | November 2023 | Dezember 2023 | Januar 2024 | Februar 2024 | März 2024 | April 2024 | |
---|---|---|---|---|---|---|---|
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma | 1 | 4 | 1 | 2 | 7 | 2 | 0 |
Zugriffe | |
---|---|
2021_Frost_etal.pdf | 128 |